Multiple Major Banks Raise Price Targets as Moderna Stock Surges Over 10%
Nashnova编辑部
Moderna surged over 10% Tuesday to $153.3, after Phase 3 data from its personalized mRNA cancer vaccine with Merck prompted Barclays and JPMorgan to sharply raise their price targets.
What happened?
Moderna (MRNA.US) closed up over 10% Tuesday at $153.3.
The catalyst: Phase 3 clinical trial data from a personalized mRNA cancer vaccine — a vaccine custom-built to each patient's tumor genetics — co-developed with Merck (MRK.US).
Multiple Wall Street banks raised their Moderna price targets immediately after the data release.
How much did the targets move?
Barclays lifted its Moderna target from $48 to $125 — a jump of over 160%.
JPMorgan raised its target from $40 to $77 — nearly doubling it.
This means → both banks had been deeply bearish on Moderna; the Phase 3 readout forced them to rebuild their valuation frameworks from scratch.
How should we read this move?
Price-target increases of this magnitude are rare in major-bank research — the data materially changed the market's view on mRNA cancer-vaccine commercialization.
In plain terms = Wall Street had largely written off this pipeline; the data now suggest it could actually generate revenue, so the math starts over.
One caveat: even after the upgrades, Barclays' $125 and JPMorgan's $77 targets still sit below the current $153.3 share price — the market has already run ahead of the analysts.
Content is for reference only, not financial advice.